Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Sofosbuvir"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 6443
Tytuł:
Sofosbuvir Suppresses the Genome Replication of DENV1 in Human Hepatic Huh7 Cells.
Autorzy:
Kurosawa M; Department of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.
Kato F; Department of Virology III, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Hishiki T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Ito S; Department of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.
Fujisawa H; Department of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.
Yamaguchi T; Department of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.
Moriguchi M; Department of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.
Hosokawa K; Department of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.
Watanabe T; Department of Virology, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan.
Saito-Tarashima N; Graduate School of Pharmaceutical Science, Tokushima University, Tokushima 770-8505, Japan.
Minakawa N; Graduate School of Pharmaceutical Science, Tokushima University, Tokushima 770-8505, Japan.
Fujimuro M; Department of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 07; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 07.
Typ publikacji:
Journal Article
MeSH Terms:
Sofosbuvir*/pharmacology
Hepatitis C*
Animals ; Cricetinae ; Chlorocebus aethiops ; Humans ; Antiviral Agents/pharmacology ; Vero Cells ; RNA-Dependent RNA Polymerase ; Virus Replication ; Hepacivirus/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Intergeneration Long-Lasting Consequences of Pre-Conceptional Exposure to Sofosbuvir on the Ovarian Tissues of F1 Offspring: Experimental Study on Rats.
Autorzy:
Hafez HA; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Mahmoud SA; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Alhmoud JF; Department of Medical Laboratory Sciences, Jordan University of Science and Technology, Irbid 22110, Jordan.
Khafaga RHM; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Kamel MA; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Shaker SA; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Sep 05; Vol. 24 (18). Date of Electronic Publication: 2023 Sep 05.
Typ publikacji:
Journal Article
MeSH Terms:
Sofosbuvir*/pharmacology
Hepatitis C*
Pregnancy ; Animals ; Rats ; Female ; Humans ; Male ; Fertilization ; Reproduction ; Cell Communication
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes.
Autorzy:
Ali RA; Zoology Department, Faculty of Science, South Valley University, Qena, Egypt.
Awadalla EA; Zoology Department, Faculty of Science, Aswan University, Aswan, Egypt.
Amin YA; Department of Theriogenology, Faculty of Veterinary Medicine, Aswan University, Aswan, Egypt. .
Fouad SS; Qena University Hospital, South Valley University, Qena, Egypt.
Ahmed MAB; Department of Anatomy, Faculty of Medicine, South Valley University, Qena, Egypt.
Hassan MH; Department of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena, Egypt.
Abdel-Kahaar E; Department of Medical Pharmacology, Faculty of Medicine, South Valley University, Qena, Egypt.; Institute of Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht-Karls-University, Heidelberg, Germany.
Abdel-Aziz RH; Department of Medical Physiology, Faculty of Medicine, South Valley University, Qena, Egypt.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 07; Vol. 14 (1), pp. 5682. Date of Electronic Publication: 2024 Mar 07.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis C, Chronic*/drug therapy
Pancreatitis*/chemically induced
Humans ; Adult ; Child ; Male ; Animals ; Rats ; Antiviral Agents/adverse effects ; Sofosbuvir/adverse effects ; Ribavirin/therapeutic use ; Hepacivirus/genetics ; Acute Disease ; Treatment Outcome ; Drug Therapy, Combination ; Semen ; Sperm Motility ; Liver Cirrhosis/complications ; Lipase/genetics ; Genotype
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China.
Autorzy:
Zhou Y; Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, No. 600 Tianhe Road , 510630, Guangzhou City, Guangdong Province, China.
Liang M; Department of Infectious disease, The First people's hospital of Foshan, Foshan City, Guangdong Province, China.
Li Y; Department of General Practice, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou City, Guangdong Province, China.
Chen X; Department of Infectious Diseases, Yangjiang Public Health Hospital, Yangjiang City, Guangdong Province, China.
Yang J; Clinical Medicine Department of Southwest Medical University, Luzhou City, Sichuan Province, China.
Bai H; Department of Infectious disease, The First people's hospital of Foshan, Foshan City, Guangdong Province, China.
Long Y; Department of Infectious Diseases, The Eighth Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, China.
Zhang X; Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, No. 600 Tianhe Road , 510630, Guangzhou City, Guangdong Province, China.
Lin C; Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, No. 600 Tianhe Road , 510630, Guangzhou City, Guangdong Province, China. .
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2024 Feb 14; Vol. 24 (1), pp. 73. Date of Electronic Publication: 2024 Feb 14.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Benzimidazoles*
Benzopyrans*
Carbamates*
Cyclopropanes*
Drug Combinations*
Hepatitis C*/drug therapy
Hepatitis C, Chronic*/genetics
Isoindoles*
Lactams, Macrocyclic*
Proline*/analogs & derivatives
Sulfonamides*
Humans ; Antiviral Agents/adverse effects ; China ; Genotype ; Hepacivirus/genetics ; Heterocyclic Compounds, 4 or More Rings/adverse effects ; Liver Cirrhosis/drug therapy ; Retrospective Studies ; Ribavirin/adverse effects ; Sofosbuvir/adverse effects ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effectiveness and safety of SOF/VEL containing rescue therapy in treating chronic HCV-GT4 patients previously failed NS5A inhibitors-based DAAs.
Autorzy:
Omar, Heba (AUTHOR)
Maksoud, Mohammed Hamdy Abdel (AUTHOR)
Goma, Ahmed A. (AUTHOR)
Hassan, Essam A. (AUTHOR)
Atta, Nancy Abdalla (AUTHOR)
Khalil, Mahmoud (AUTHOR)
Hegazy, Mohamed Soliman (AUTHOR)
Zaky, Samy (AUTHOR)
Esmat, Gamal (AUTHOR)
Pokaż więcej
Źródło:
Egyptian Liver Journal. 3/11/2024, Vol. 14 Issue 1, p1-9. 9p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.
Autorzy:
Amjed S; University Institute of Medical Laboratory Technology, Faculty of Allied Health Sciences, The University of Lahore, Raiwind Road Campus, Lahore, Pakistan. .; Medical Laboratory Technology Department, Faculty of Rehabilitation and Allied Health Sciences, RIPHAH International University, Gulberg Campus, Lahore, Pakistan. .
Saleem HGM; University Institute of Medical Laboratory Technology, Faculty of Allied Health Sciences, The University of Lahore, Raiwind Road Campus, Lahore, Pakistan.; Medical Laboratory Technology Department, Faculty of Rehabilitation and Allied Health Sciences, RIPHAH International University, Gulberg Campus, Lahore, Pakistan.
Ullah S; University Institute of Medical Laboratory Technology, Faculty of Allied Health Sciences, The University of Lahore, Raiwind Road Campus, Lahore, Pakistan.
Latif S; Gastroenterology Department, Akthar Saeed Medical and Dental College, Lahore, Pakistan.
Shabana; Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan.
Jafar J; Specilized Health Care and Medical Education Department, Lahore, Punjab, Pakistan.
Waqar AB; University Institute of Medical Laboratory Technology, Faculty of Allied Health Sciences, The University of Lahore, Raiwind Road Campus, Lahore, Pakistan.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2024 Mar 11; Vol. 24 (1), pp. 301. Date of Electronic Publication: 2024 Mar 11.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis C, Chronic*/drug therapy
Hepatitis C, Chronic*/genetics
Anemia*/chemically induced
Anemia*/genetics
Hepatitis C*/drug therapy
Humans ; Ribavirin/adverse effects ; Sofosbuvir/adverse effects ; Antiviral Agents/adverse effects ; Inosine Triphosphatase ; Hepacivirus/genetics ; Prospective Studies ; Polymorphism, Single Nucleotide ; Pyrophosphatases/genetics ; Pyrophosphatases/therapeutic use ; Genotype ; Hemoglobins/genetics ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders.
Autorzy:
Wedemeyer H; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, OE6810, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Di Marco V; University of Palermo, Piazza Marina, 61, 90133 Palermo, Italy.
Garcia-Retortillo M; Liver Section, Gastroenterology Department, Hospital del Mar-Parc de Salut Mar, Hospital del Mar Medical Research Institute (IMIM), C/ del Dr. Aiguader, 88, 08003 Barcelona, Spain.
Teti E; Tor Vergata University, Via Cracovia, 50, 00133 Rome, Italy.
Fraser C; Cool Aid Community Health Centre, 713 Johnson St, Victoria, BC V8W 1M8, Canada.
Morano Amado LE; Unit of Infectious Diseases, Álvaro Cunqueiro University Hospital, Estrada de Clara Campoamor, 341, 36312 Vigo, Spain.
Rodriguez-Tajes S; Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, C. de Villarroel, 170, 08036 Barcelona, Spain.
Acosta-López S; Digestive Diseases, Hospital Nuestra Señora de Candelaria, Ctra. Gral. del Rosario, 145, 38010 Tenerife, Spain.
O'Loan J; Medeco Inala & Kombi Clinic, 55b/156 Inala Ave, Brisbane, QLD 4077, Australia.; School of Medicine, University of Queensland, St Lucia, Brisbane, QLD 4072, Australia.
Milella M; Clinic of Infectious Diseases, University of Bari, Piazza Umberto I, 1, 70121 Bari, Italy.
Buti M; Liver Unit, Vall d'Hebron University Hospital, and CIBEREHD del Instituto Carlos III, Barcelona, Spain.
Guerra-Veloz MF; Virgen Macarena University Hospital, Av. Dr. Fedriani, 3, 41003 Seville, Spain.; Clinical Research Fellow in Hepatology at King's College Hospital, Denmark Hill, London SE5 9RS, UK.
Ramji A; University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Fenech M; Queensland Injectors Health Network (QuIHN), Treatment and Management Programme, 1 Hamilton Pl, Bowen Hills, Brisbane, QLD 4006, Australia.
Martins A; Hospital Prof. Dr. Fernando Fonseca, IC19, 2720-276 Amadora, Portugal.
Borgia SM; Infectious Diseases, William Osler Health System, 2100 Bovaird Dr E, Brampton, ON L6R 3J7, Canada.
Vanstraelen K; Gilead Sciences Europe Ltd., Stockley Park, 2 Roundwood Ave, Hayes, Uxbridge UB11 1AS, UK.
Mertens M; Gilead Sciences Europe Ltd., Stockley Park, 2 Roundwood Ave, Hayes, Uxbridge UB11 1AS, UK.
Hernández C; Gilead Sciences Europe Ltd., Stockley Park, 2 Roundwood Ave, Hayes, Uxbridge UB11 1AS, UK.
Ntalla I; Gilead Sciences Europe Ltd., Stockley Park, 2 Roundwood Ave, Hayes, Uxbridge UB11 1AS, UK.
Ramroth H; Gilead Sciences Europe Ltd., Stockley Park, 2 Roundwood Ave, Hayes, Uxbridge UB11 1AS, UK.
Milligan S; Trio Health Analytics, 1025 Cannon Street, Suite 2C, Louisville, CO 80027, USA.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 Nov 11; Vol. 14 (11). Date of Electronic Publication: 2022 Nov 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents*/therapeutic use
Hepatitis C*/complications
Hepatitis C*/drug therapy
Sofosbuvir*/therapeutic use
Mental Disorders*/complications
Humans ; Genotype ; Hepacivirus
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment.
Autorzy:
Ezzat WM; Internal Medicine Department, National Research Centre, Cairo, Egypt.
Amr KS; Medical Molecular Genetics Department, National Research Centre, El-Buhouth St., Dokki, 12622, Cairo, Egypt. .
Tawfeek S; Internal Medicine Department, National Research Centre, Cairo, Egypt.
Elbatae H; Tropical Medicine Department, Kafr Elsheikh University, Kafr Elsheikh, Egypt.
Bayomi EA; Medical Molecular Genetics Department, National Research Centre, El-Buhouth St., Dokki, 12622, Cairo, Egypt.
Heiba A; Internal Medicine Department, National Research Centre, Cairo, Egypt.
Elhosary Y; Internal Medicine Department, National Research Centre, Cairo, Egypt.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2024 Jan 09; Vol. 24 (1), pp. 67. Date of Electronic Publication: 2024 Jan 09.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis C, Chronic*/drug therapy
MicroRNAs*/genetics
Hepatitis C*
Humans ; Sofosbuvir/therapeutic use ; Antiviral Agents/therapeutic use ; Egypt ; Hepacivirus/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis.
Autorzy:
Elshafie S; Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Georgia, USA.; Central Administration for Drug Control, Egyptian Drug Authority, Cairo, Egypt.
Trivedi-Kapoor R; Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Georgia, USA.
Ebell M; Department of Epidemiology, College of Public Health, University of Georgia, Athens, Georgia, USA.
Pokaż więcej
Źródło:
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2022 Aug; Vol. 47 (8), pp. 1149-1158. Date of Electronic Publication: 2022 Jun 08.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Hepatitis C*/drug therapy
Ribavirin*/adverse effects
Sofosbuvir*/adverse effects
Antiviral Agents/adverse effects ; Drug Therapy, Combination ; Genotype ; Hepacivirus ; Hepatitis C, Chronic/drug therapy ; Humans ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocol.
Autorzy:
Arif A; Doctor's Plaza, Khayaban E Iqbal Block 9 DO Talwar, Karachi, Clifton, 75600, Pakistan. .
Hasnain A; Department of Medicine, Aga Khan University, Stadium Road, Karachi, 74800, Pakistan.
Chaudhry A; Gut & Liver Center, Chaudhry Hospital and PARSA Trust Liver Clinic, Gujranwala, Pakistan.
Asim M; Dow University of Health Sciences, Karachi, Pakistan.
Shafqat MN; Gut & Liver Center, Chaudhry Hospital and PARSA Trust Liver Clinic, Gujranwala, Pakistan.
Altaf A; Dow University of Health Sciences, Karachi, Pakistan.
Saba N; Department of Medicine, Aga Khan University, Stadium Road, Karachi, 74800, Pakistan.
Kemos P; Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Ansari MA; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Barnes E; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Metcalfe C; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Vickerman P; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Qureshi H; Doctor's Plaza, Khayaban E Iqbal Block 9 DO Talwar, Karachi, Clifton, 75600, Pakistan.
Hamid S; Department of Medicine, Aga Khan University, Stadium Road, Karachi, 74800, Pakistan.
Choudhry AA; Gut & Liver Center, Chaudhry Hospital and PARSA Trust Liver Clinic, Gujranwala, Pakistan.
Niaz SK; Dow University of Health Sciences, Karachi, Pakistan.
Foster GR; Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Choudhry N; Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Pokaż więcej
Źródło:
BMC public health [BMC Public Health] 2023 Dec 18; Vol. 23 (1), pp. 2529. Date of Electronic Publication: 2023 Dec 18.
Typ publikacji:
Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepatitis C*/diagnosis
Hepatitis C*/drug therapy
Hepatitis C*/epidemiology
Hepatitis C, Chronic*/drug therapy
Humans ; Antiviral Agents/therapeutic use ; Cohort Studies ; Hepacivirus/genetics ; Multicenter Studies as Topic ; Observational Studies as Topic ; Pakistan/epidemiology ; Prospective Studies ; Quality of Life ; Reinfection/drug therapy ; Sofosbuvir/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Investigation of the effect of verapamil on the regional absorption of sofosbuvir from rabbit intestine in situ.
Autorzy:
Mohsen NM; Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Tanta, Tanta, 31111, Egypt.
El-Din EEZ; Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Tanta, Tanta, 31111, Egypt.; Department of Pharmaceutics, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt.
Osman MA; Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Tanta, Tanta, 31111, Egypt.
Ashmawy SM; Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Tanta, Tanta, 31111, Egypt. .
Pokaż więcej
Źródło:
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences [Daru] 2022 Jun; Vol. 30 (1), pp. 49-58. Date of Electronic Publication: 2022 Jan 13.
Typ publikacji:
Journal Article
MeSH Terms:
Sofosbuvir*/pharmacology
Verapamil*/metabolism
Verapamil*/pharmacology
Animals ; Humans ; Intestinal Absorption ; Intestines ; Jejunum/metabolism ; Rabbits
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Direct-Acting Antiviral Drug Modulates the Mitochondrial Biogenesis in Different Tissues of Young Female Rats.
Autorzy:
Hafez HA; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Atoom AM; Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19111, Jordan.
Khafaga RHM; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Shaker SA; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Kamel MA; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Assem NM; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Mahmoud SA; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Oct 31; Vol. 24 (21). Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis C, Chronic*/drug therapy
Hepatitis C*/drug therapy
Female ; Rats ; Animals ; Antiviral Agents ; Organelle Biogenesis ; Treatment Outcome ; Rats, Wistar ; Sofosbuvir/therapeutic use ; Hepacivirus/genetics ; Drug Therapy, Combination ; Genotype
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
Autorzy:
Flamm S; Department of Internal Medicine, Division of Digestive Diseases and Nutrition, Rush University Medical Center, Chicago, IL 60612, USA.
Lawitz E; Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX 78215, USA.
Borg B; Southern Therapy and Advanced Research LLC, Jackson, MS 39216, USA.
Charlton M; Intermountain Medical Center, Murray, UT 84107, USA.
Landis C; Division of Gastroenterology and Hepatology, University of Washington, Seattle, WA 98101, USA.
Reddy KR; Department of Medicine, Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Shiffman M; Bon Secours Mercy Health, Liver Institute of Virginia, Richmond, VA 23226, USA.
Alsina A; Tampa General Medical Group, Tampa, FL 33609, USA.
Chang C; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Ravendhran N; Digestive Disease Associates, Catonsville, MD 21228, USA.
Hernandez C; Gilead Sciences, Inc., Foster City, CA 94404, USA.
Hézode C; Gilead Sciences, Inc., Foster City, CA 94404, USA.
Scherbakovsky S; Gilead Sciences, Inc., Foster City, CA 94404, USA.
Mercier RC; Gilead Sciences, Inc., Foster City, CA 94404, USA.
Samuel D; Centre Hépatobiliaire, Hôpital Paul-Brousse, Inserm Research Unit 1193, Université Paris-Saclay, 94800 Villejuif, France.
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Sep 29; Vol. 15 (10). Date of Electronic Publication: 2023 Sep 29.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepatitis C*/drug therapy
Hepatitis C, Chronic*/complications
Hepatitis C, Chronic*/drug therapy
Adult ; Humans ; Sofosbuvir/adverse effects ; Ribavirin/adverse effects ; Hepacivirus/genetics ; Antiviral Agents/adverse effects ; Treatment Outcome ; Genotype ; Drug Therapy, Combination
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Heparin Precursors with Reduced Anticoagulant Properties Retain Antiviral and Protective Effects That Potentiate the Efficacy of Sofosbuvir against Zika Virus Infection in Human Neural Progenitor Cells.
Autorzy:
Pagani, Isabel (AUTHOR)
Ottoboni, Linda (AUTHOR)
Panina-Bordignon, Paola (AUTHOR)
Martino, Gianvito (AUTHOR)
Poli, Guido (AUTHOR)
Taylor, Sarah (AUTHOR)
Turnbull, Jeremy E. (AUTHOR)
Yates, Edwin (AUTHOR)
Vicenzi, Elisa (AUTHOR)
Pokaż więcej
Źródło:
Pharmaceuticals (14248247). Oct2023, Vol. 16 Issue 10, p1385. 16p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Histopathological Effect of Sofosbuvir as Compared to Sofosbuvir Combined with Ribavirin on Submandibular Salivary Glands of Adult Albino Rats (Histological and Immunofluorescent Study).
Autorzy:
Shawkat, Alaa Ossama
Ali, Zoba H.
Bashir, Maha H.
Pokaż więcej
Alternatywny tytuł:
التأثيرالهيستوباثولوجي لعقار السوفوسبفير مقارنة بالسوفوسبفيرمع الريبافيرين على انسجة غدد تحت الفك للفئران البيضاء البالغة(دراسة هستولوجية ومناعية بواسطة ميكروسكوب فلوري).
Źródło:
Egyptian Journal of Histology. Sep2023, Vol. 46 Issue 3, p1262-1271. 10p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Simultaneous spectrophotometric determination of recombined sofosbuvir, ledipasvir and paracetamol together as commonly repurposed drugs for COVID-19 treatment.
Autorzy:
Gamal, Sherif (AUTHOR)
Mandour, Asmaa A. (AUTHOR)
Mohamed, Gehad G. (AUTHOR)
Salih, Said A. (AUTHOR)
Ahmed, Dina A. (AUTHOR)
Pokaż więcej
Źródło:
Future Journal of Pharmaceutical Sciences. 8/17/2023, Vol. 9 Issue 1, p1-10. 10p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
HPLC-UV and TLC-Densitometry Methods for Simultaneous Determination of Sofosbuvir and Daclatasvir: Application to Darvoni® Tablet.
Autorzy:
Fayed AS; Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr-El Aini Street, 11562 Cairo, Egypt.
Hegazy MA; Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr-El Aini Street, 11562 Cairo, Egypt.
Kamel EB; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, 11829 Cairo, Egypt.
Eissa MS; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, 11829 Cairo, Egypt.
Pokaż więcej
Źródło:
Journal of chromatographic science [J Chromatogr Sci] 2022 Jul 12; Vol. 60 (6), pp. 606-612.
Typ publikacji:
Journal Article
MeSH Terms:
Antiviral Agents*/analysis
Sofosbuvir*/analysis
Carbamates ; Chromatography, High Pressure Liquid/methods ; Chromatography, Thin Layer/methods ; Densitometry/methods ; Imidazoles ; Pyrrolidines ; Reproducibility of Results ; Tablets ; Valine/analogs & derivatives
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol.
Autorzy:
Wang YK; Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Department of Pharmacy, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Department of Pharmacy, National Yang Ming Chiao Tung University Hospital, Yilan, Taiwan.
Wang YW; Healthcare Center, Taipei Veterans General Hospital, Taipei, Taiwan.
Lu CL; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Huang YH; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Institute of Clinical Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Hou MC; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Chang YL; Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan.; Department of Pharmacy, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Lee WP; Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan. .; Institute of Biochemistry and Molecular Biology, College of Life Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan. .
Lan KH; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. .; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. .; Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jun 15; Vol. 12 (1), pp. 9942. Date of Electronic Publication: 2022 Jun 15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cholesterol, LDL*/drug effects
Cholesterol, LDL*/metabolism
HIV Infections*/drug therapy
Hepatitis C, Chronic*/drug therapy
Sofosbuvir*/pharmacology
Antiviral Agents/pharmacology ; Cholesterol/metabolism ; Drug Therapy, Combination ; Genotype ; Hepacivirus ; Humans ; Retrospective Studies ; Ribavirin/pharmacology ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.
Autorzy:
Boyer S; Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Faculté de Médecine, 27 Bd Jean Moulin, 13 005, Marseille, France. .
Baudoin M; Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Faculté de Médecine, 27 Bd Jean Moulin, 13 005, Marseille, France.
Nishimwe ML; Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Faculté de Médecine, 27 Bd Jean Moulin, 13 005, Marseille, France.; ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France.
Santos M; Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Faculté de Médecine, 27 Bd Jean Moulin, 13 005, Marseille, France.
Lemoine M; Department of Metabolism, Digestion and Reproduction, Division of Digestive Diseases, Section of Hepatology and Gastroenterology, St Mary's Hospital, Imperial College, London, UK.
Maradan G; Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Faculté de Médecine, 27 Bd Jean Moulin, 13 005, Marseille, France.; ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France.
Sylla B; IMEA, Paris, France.
Kouanfack C; Hôpital de Jour, Hôpital Central de Yaoundé, Yaoundé, Cameroon.; Faculté de Médecine et des Sciences Pharmaceutiques, Université de Dschang, Dschang, Cameroon.
Carrieri P; Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Faculté de Médecine, 27 Bd Jean Moulin, 13 005, Marseille, France.
Mourad A; Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Faculté de Médecine, 27 Bd Jean Moulin, 13 005, Marseille, France.
Rouveau N; ANRS, Paris, France.
Moh R; MEREVA, PACCI Abidjan, Abidjan, Côte d'Ivoire.; Unité Pédagogique de Dermatologie et Infectiologie, UFR des sciences médicales, Abidjan, Côte d'Ivoire.
Seydi M; Service des Maladies Infectieuses et Tropicales, CHU Fann, Dakar, Sénégal.
Attia A; Service d'hépatologie, CHU Yopougon, Abidjan, Côte d'Ivoire.
Woode ME; Centre for Health Economics, Monash University, Melbourne, Australia.
Lacombe K; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.; APHP, Hôpital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris, France.
Pokaż więcej
Źródło:
BMC health services research [BMC Health Serv Res] 2022 Mar 05; Vol. 22 (1), pp. 303. Date of Electronic Publication: 2022 Mar 05.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis C, Chronic*/drug therapy
Sofosbuvir*/therapeutic use
Antiviral Agents/therapeutic use ; Cost-Benefit Analysis ; Drug Therapy, Combination ; Genotype ; Hepacivirus/genetics ; Humans ; World Health Organization
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 6443

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies